<DOC>
	<DOC>NCT01658956</DOC>
	<brief_summary>The study aims to confirm that a reduced dosage of GCSF is effective in preventing febrile neutropenia among patients with breast cancer, treated with chemotherapy and presenting with a low to moderate risk of developing febrile neutropenia.</brief_summary>
	<brief_title>Effectiveness of Reduced GCSF Dosing in Patients With a Low to Moderate Risk of Febrile Neutropenia</brief_title>
	<detailed_description />
	<mesh_term>Neutropenia</mesh_term>
	<mesh_term>Febrile Neutropenia</mesh_term>
	<criteria>Breast cancer Chemotherapy administration (new line) Chemotherapy type : FEC, EC, AC, docetaxel containing regimen Chemotherapy setting : adjuvant or neoadjuvant Eligibility to receive reimbursed GCSF</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>GCSF</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Breast cancer</keyword>
	<keyword>Prophylaxis</keyword>
</DOC>